H

Healius Ltd
ASX:HLS

Watchlist Manager
Healius Ltd
ASX:HLS
Watchlist
Price: 0.975 AUD Market Closed
Market Cap: 708m AUD

Intrinsic Value

The intrinsic value of one HLS stock under the Base Case scenario is 3.068 AUD. Compared to the current market price of 0.975 AUD, Healius Ltd is Undervalued by 68%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

HLS Intrinsic Value
3.068 AUD
Undervaluation 68%
Intrinsic Value
Price
H
Worst Case
Base Case
Best Case

Valuation History
Healius Ltd

What is Valuation History?
Ask AI Assistant
What other research platforms think about HLS?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is HLS valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Healius Ltd.

Explain Valuation
Compare HLS to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Healius’s heavy reliance on government reimbursements for pathology and diagnostic imaging services poses a significant risk if future Medicare policy changes or cuts reduce revenue streams.

Increasing competition from Sonic Healthcare and other private pathology operators could pressure Healius’s pricing power and reduce its market share, especially if bulk-billing rates come under scrutiny.

Delays or challenges in successfully integrating and optimizing its newly restructured day hospital and diagnostic centers could weaken Healius’s broader service offering, leading to slower growth than anticipated.

Bull Theses

Healius’s strong position in the Australian pathology sector, combined with cost optimization efforts, could yield competitive margins and sustainable growth even if parts of the healthcare budget tighten.

The company’s pivot away from large-scale medical centers toward more specialized day hospitals aligns with rising demand for short-stay procedures and can capture a larger pool of private patients.

Its extensive geographic footprint and recognized service quality give Healius an opportunity to cross-sell integrated healthcare services (pathology, imaging, and day hospitals), underpinning stronger patient retention and profitability.

Show More Less
How do you feel about HLS?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Healius Ltd

Current Assets 251.9m
Cash & Short-Term Investments 57.2m
Receivables 164.9m
Other Current Assets 29.8m
Non-Current Assets 1.5B
Long-Term Investments 3.2m
PP&E 938.5m
Intangibles 486.6m
Other Non-Current Assets 96.8m
Current Liabilities 446.2m
Accounts Payable 133.9m
Other Current Liabilities 312.3m
Non-Current Liabilities 742.9m
Long-Term Debt 730.5m
Other Non-Current Liabilities 12.4m
Efficiency

Free Cash Flow Analysis
Healius Ltd

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Healius Ltd

Revenue
1.3B AUD
Cost of Revenue
-214m AUD
Gross Profit
1.1B AUD
Operating Expenses
-1.1B AUD
Operating Income
200k AUD
Other Expenses
-151.4m AUD
Net Income
-151.2m AUD
Fundamental Scores

HLS Profitability Score
Profitability Due Diligence

Healius Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin
Strong 3Y Average Gross Margin
Declining Gross Margin
Low 3Y Average Operating Margin
31/100
Profitability
Score

Healius Ltd's profitability score is 31/100. The higher the profitability score, the more profitable the company is.

HLS Solvency Score
Solvency Due Diligence

Healius Ltd's solvency score is 32/100. The higher the solvency score, the more solvent the company is.

Long-Term Solvency
Average D/E
Short-Term Solvency
Positive Net Debt
32/100
Solvency
Score

Healius Ltd's solvency score is 32/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

HLS Price Targets Summary
Healius Ltd

Wall Street analysts forecast HLS stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for HLS is 0.836 AUD with a low forecast of 0.606 AUD and a high forecast of 1.103 AUD.

Lowest
Price Target
0.606 AUD
38% Downside
Average
Price Target
0.836 AUD
14% Downside
Highest
Price Target
1.103 AUD
13% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for HLS is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one HLS stock?

The intrinsic value of one HLS stock under the Base Case scenario is 3.068 AUD.

Is HLS stock undervalued or overvalued?

Compared to the current market price of 0.975 AUD, Healius Ltd is Undervalued by 68%.

Back to Top